Clinical Trials on Calorie Overload in South Africa

Total 14 results

Novartis Pharmaceuticals

Terminated

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study (MACS1574)

Myelodysplastic Syndrome | Transfusional Iron Overload

Spain, France, Italy, South Africa
Novartis Pharmaceuticals

Completed

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

Transfusion-dependent Iron Overload

Egypt, Greece, Hong Kong, Taiwan, Germany, United Kingdom, Belgium, Italy, Spain, France, Israel, Korea, Republic of, Turkey, China, Australia, Denmark, Austria, Switzerland, Netherlands, South Africa, Lebanon, Malaysia, Thailand
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Transfusion-dependent Anemia

Egypt, Hungary, Turkey, United States, Bulgaria, Italy, Belgium, Russian Federation, Philippines, France, Malaysia, India, Oman, Panama, Lebanon, Thailand, Tunisia
La Jolla Pharmaceutical Company

Terminated

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

Beta-Thalassemia

Australia, Thailand, United States, Greece, Italy, Lebanon, Turkey, United Kingdom
Woolcock Institute of Medical Research

Recruiting

Biomarkers of Dementia in Chronic Sleep and Breathing Disorders (ORACLE)

OSA | COPD | Overlap Syndrome

Australia
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Iron Overload | Hereditary Hemochromatosis

United States, Germany, Italy, Australia, Canada, France
Novartis Pharmaceuticals

Completed

An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)

Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia

Australia
ApoPharma

Terminated

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Iron Overload | Sickle Cell Disease | Other Anemias

United States, United Kingdom, Egypt, Canada, Saudi Arabia
La Jolla Pharmaceutical Company
PRA Health Sciences

Completed

A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

Hereditary Hemochromatosis

United States, Australia, France, United Kingdom
Novartis Pharmaceuticals

Completed

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Anemia, Sickle Cell

United States
ApoPharma

Terminated

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias (FIRST)

Iron Overload | Sickle Cell Disease | Other Anemias

United States, Turkey, United Kingdom, Egypt, Saudi Arabia, Brazil, Canada, Tunisia
Novartis Pharmaceuticals

Completed

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Iron Overload | Sickle Cell Disease | Hemolytic Anemia

United States, Canada
St. Jude Children's Research Hospital
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Stroke With Transfusions Changing to Hydroxyurea

Hematologic Diseases | Anemia, Sickle Cell | Cerebrovascular Accident | Hemochromatosis

United States
Bristol-Myers Squibb

Completed

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Dermatomyositis | Polymyositis | Autoimmune Necrotizing Myopathy | Overlap Myositis | Juvenile Myositis Above the Age of 18

France, United States, Australia, Brazil, Czechia, Germany, Italy, Japan, Korea, Republic of, Mexico, Sweden

Clinical Trials on Calorie Overload in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations